TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14649401

Group type: EXPERIMENTAL
Intervention: Warfarin treatment maintained
Number of subjects: 70

Group type: COMPARATOR
Intervention: Warfarin stopped prior to surgery
Number of subjects: 70
Study: 11030374

Group type: EXPERIMENTAL
Intervention: Oral food challenges with cow's milk, hen's egg, wheat, and soy
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Parenteral medication
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Oral medication
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Specific IgE levels
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Patient history of food allergy
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Positive patient history and high specific IgE levels
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Establishing intravenous access
Number of subjects: 204
Study: 9563239

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBT)
Number of subjects: 0
Study: 7812205

Group type: EXPERIMENTAL
Intervention: Induction treatment with human lymphoblastoid IFN alpha-n1, 3 MU/mq daily for a median of 5.7 months
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Maintenance treatment with human lymphoblastoid IFN alpha-n1, 3 MU/mq weekly
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Retreatment with human lymphoblastoid IFN alpha-n1 after relapse
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Third induction treatment with human lymphoblastoid IFN alpha-n1
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 89
Study: 3287839

Group type: EXPERIMENTAL
Intervention: 1-week treatment with pivampicillin plus pivmecillinam
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 3-week treatment with pivampicillin plus pivmecillinam
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 61
Study: 30300870

Group type: COMPARATOR
Intervention: Mindfulness only group (n = 27)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Mindfulness + plain-text reminder group (n = 24)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Mindfulness + enhanced text reminder with animal meme group (n = 25)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 101
Study: 28188585

Group type: EXPERIMENTAL
Intervention: Interpersonal behavior change strategies (social support, friendly social comparison; yes)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intrapersonal behavior change strategies (goal setting, barriers management; yes)
Number of subjects: 102

Group type: COMPARATOR
Intervention: No interpersonal behavior change strategies (no)
Number of subjects: 102

Group type: COMPARATOR
Intervention: No intrapersonal behavior change strategies (no)
Number of subjects: 102
Study: 26601555

Group type: EXPERIMENTAL
Intervention: Sevoflurane (1-2%)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Propofol (0.2-0.5 mg/kg)
Number of subjects: 57
Study: 23188886

Group type: EXPERIMENTAL
Intervention: Parent‐Child Interaction Therapy (PCIT)
Number of subjects: 44
Study: 21480412

Group type: EXPERIMENTAL
Intervention: Saffron (100 mg daily for 6 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 18453877

Group type: EXPERIMENTAL
Intervention: semiliquid diet
Number of subjects: 60

Group type: COMPARATOR
Intervention: clear feeds
Number of subjects: 60
Study: 16547654

Group type: EXPERIMENTAL
Intervention: Medication with beta blockers
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Class III antiarrhythmic agents (sotalol and amiodarone)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Overall survival rate
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Sudden death
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Non-sudden cardiac causes of death
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Non-cardiac fatal events
Number of subjects: 429

Group type: COMPARATOR
Intervention: Structural heart disease
Number of subjects: 429

Group type: COMPARATOR
Intervention: Left ventricular ejection fraction
Number of subjects: 429
Study: 14535873

Group type: EXPERIMENTAL
Intervention: Esomeprazole 2 x 20 mg with clarithromycin 2 x 250 mg and metronidazole 2 x 400 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Omeprazole 2 x 20 mg with clarithromycin 2 x 250 mg and metronidazole 2 x 400 mg
Number of subjects: 80
Study: 10982170

Group type: EXPERIMENTAL
Intervention: Four large multicenter study protocols
Number of subjects: 120
Study: 8937280

Group type: EXPERIMENTAL
Intervention: Benznidazole (7.5 mg/kg daily for 60 days)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Benznidazole
Number of subjects: 130
Study: 8299527

Group type: EXPERIMENTAL
Intervention: lisinopril (5 mg/d, sometimes increased to 10 mg/d after 3 weeks)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: captopril (twice daily 12.5 mg, sometimes increased to twice 25 mg after 3 weeks)
Number of subjects: 11

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study: 3043570

Group type: EXPERIMENTAL
Intervention: Relaxation with Guided Imagery (RGI)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (quiet period)
Number of subjects: 24
Study: 30989422

Group type: EXPERIMENTAL
Intervention: rs1800796 polymorphism of the IL-6 gene
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control group (subjects without MetS)
Number of subjects: 182
Study: 28320259

Group type: EXPERIMENTAL
Intervention: Levosimendan (0.025 to 0.2 μg/kg/min continuous infusion)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 506
Study: 26273134

Group type: EXPERIMENTAL
Intervention: isoflurane + dexmedetomidine (DISO)
Number of subjects: 49

Group type: COMPARATOR
Intervention: isoflurane + saline (NISO)
Number of subjects: 49
Study: 23043851

Group type: EXPERIMENTAL
Intervention: Double-balloon enteroscopy (DBE)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Spiral enteroscopy (SE)
Number of subjects: 26
Study: 21964228

Group type: EXPERIMENTAL
Intervention: Multisensory stimulation (MSS) program, 55 minutes, twice a week for 10 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 51
Study: 19075728

Group type: EXPERIMENTAL
Intervention: Paroxetine treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 60
Study: 16573792

Group type: EXPERIMENTAL
Intervention: Low cholesterol diet (300 mg/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High cholesterol diet (1300 mg/day)
Number of subjects: 15
Study: 12656549

Group type: EXPERIMENTAL
Intervention: Continuous infusion of propofol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Bolus administration of propofol
Number of subjects: 18
Study: 11008222

Group type: EXPERIMENTAL
Intervention: Ribavirin (600 mg/day for 8 weeks, followed by 1,000 mg/day for 8 weeks, and then 1,200 mg/day for 8 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ribavirin (in second phase for patients who received placebo)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 39
Study: 8956115

Group type: EXPERIMENTAL
Intervention: Individualized Naughton's protocol (Protocol B)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard Naughton's protocol (Protocol A)
Number of subjects: 11
Study: 1568523

Group type: EXPERIMENTAL
Intervention: 10 mg/kg cefetamet pivoxil twice daily (n = 18)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 20 mg/kg cefetamet pivoxil twice daily (n = 8)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 30-50 mg/kg amoxycillin/clavulanic acid three times daily (n = 11)
Number of subjects: 37
Study: 6486705

Group type: EXPERIMENTAL
Intervention: Dietary supplementation with iron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plasma ferritin estimations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blood haemoglobin estimations
Number of subjects: 0
Study: 31145713

Group type: EXPERIMENTAL
Intervention: cPP (central pulse pressure) measured with a 6m long tubing during MRI acquisition
Number of subjects: 38

Group type: COMPARATOR
Intervention: bPP (brachial pulse pressure) measured with 2 and 6m long tubing
Number of subjects: 38
Study: 29550566

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg daily
Number of subjects: 157

Group type: COMPARATOR
Intervention: Sunitinib 50 mg daily (4 weeks on/2 weeks off)
Number of subjects: 157
Study: 27865358

Group type: EXPERIMENTAL
Intervention: 3 mg monacolin K from RYR and 200 μg folic acid per day
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 24385133

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD)
Number of subjects: 0
Study: 21951325

Group type: EXPERIMENTAL
Intervention: Technosphere Insulin (TI)
Number of subjects: 730

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 730
Study: 19438927

Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG) 75 mg/kg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG) 150 mg/kg
Number of subjects: 14

Group type: COMPARATOR
Intervention: NaCl (24 mg/kg, placebo)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High MSG session
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Low MSG session
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (NaCl)
Number of subjects: 14
Study: 17276178

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg/day)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control (no statin)
Number of subjects: 121
Study: 15649723

Group type: EXPERIMENTAL
Intervention: Wound drain (group a)
Number of subjects: 143

Group type: COMPARATOR
Intervention: No wound drain (group b)
Number of subjects: 143
Study: 12424509

Group type: EXPERIMENTAL
Intervention: Aggressive management of risk factors such as hypertension, dyslipidemia, and platelet dysfunction in diabetics
Number of subjects: 0
Study: 10090633

Group type: EXPERIMENTAL
Intervention: 8-week strength training programme (3 sets of 8 repetitions at 80% of one repetition maximum, 3 days a week)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 8-week strength training programme
Number of subjects: 32
Study: 7812004

Group type: EXPERIMENTAL
Intervention: Fluorescence in situ hybridization (FISH) method
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional G‐banding method
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Two‐round nested reverse transcription polymerase chain reaction assay
Number of subjects: 10
Study: 2190507

Group type: EXPERIMENTAL
Intervention: 15-HETE
Number of subjects: 10

Group type: COMPARATOR
Intervention: Diluent (sodium phosphate buffer)
Number of subjects: 10
Study: 7032828

Group type: EXPERIMENTAL
Intervention: Guanfacine (1‐‐5 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Post-treatment placebo period
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Abrupt discontinuation of guanfacine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clopamide (given concurrently to two patients)
Number of subjects: 20
Study: 30433845

Group type: EXPERIMENTAL
Intervention: Multi-component communication-based intervention including presumptive approach, motivational interviewing, and a fact sheet.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-component communication-based intervention.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified).
Number of subjects: 0
Study: 28700791

Group type: EXPERIMENTAL
Intervention: Tramadol ER
Number of subjects: 103

Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 103

Group type: COMPARATOR
Intervention: Buprenorphine
Number of subjects: 103
Study: 25887078

Group type: EXPERIMENTAL
Intervention: Health coaching intervention (20-hour sessions plus follow-up)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 360
Study: 24005134

Group type: EXPERIMENTAL
Intervention: Levobupivacaine hydrochloride (5 mL, chirocaine 25 mg/10 mL) soaked PVA sponge
Number of subjects: 41

Group type: COMPARATOR
Intervention: Saline (5 mL) soaked PVA sponge
Number of subjects: 41
Study: 21232620

Group type: EXPERIMENTAL
Intervention: Realigning BioSkin Q Brace with patellar realigning strap applied
Number of subjects: 80

Group type: COMPARATOR
Intervention: BioSkin Q Brace with patellar realigning strap removed (Control)
Number of subjects: 80
Study: 19435690

Group type: EXPERIMENTAL
Intervention: S-GemOx (gemcitabine 1,000 mg/m2, 100-minute infusion D1 followed by oxaliplatin 100 mg/m2, 120-minute infusion)
Number of subjects: 57

Group type: COMPARATOR
Intervention: GemOx (Gem D1 and ox D2)
Number of subjects: 57
Study: 16963671

Group type: EXPERIMENTAL
Intervention: Montelukast, 10 mg/d for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15019314

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 275

Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 275
Study: 11407865

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone alone or together with glutamine with or without a low-fat diet containing high-carbohydrate (fibre)
Number of subjects: 47
Study: 9208337

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide plus sotalol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide plus captopril
Number of subjects: 40
Study: 7960545

Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy using colloid agents labelled with gold and technetium (99mTc‐pertechnetate)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy
Number of subjects: 181

Group type: COMPARATOR
Intervention: Transperitoneal lymphadenectomy
Number of subjects: 181
Study: 3794134

Group type: EXPERIMENTAL
Intervention: Nutritional supplement
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no nutritional supplement)
Number of subjects: 14
Study: 29019046

Group type: COMPARATOR
Intervention: Reminder letter
Number of subjects: 2772

Group type: EXPERIMENTAL
Intervention: Live phone call
Number of subjects: 2772

Group type: EXPERIMENTAL
Intervention: Text messages
Number of subjects: 2772
Study: 27744424

Group type: EXPERIMENTAL
Intervention: Exposure with eyes moving while fixating on the therapist's moving hand (EM)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Exposure with eyes fixating on the therapist's nonmoving hand (EF)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Exposure without explicit visual focus of attention (EC)
Number of subjects: 139
Study: 24634285

Group type: EXPERIMENTAL
Intervention: Tirasemtiv
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23349548

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (CGM)
Number of subjects: 154
Study: 20102257

Group type: EXPERIMENTAL
Intervention: Online assessment via telerehabilitation application
Number of subjects: 61
Study: 18636354

Group type: EXPERIMENTAL
Intervention: Somatostatin combined with oral vancomycin
Number of subjects: 58

Group type: COMPARATOR
Intervention: Traditional treatment
Number of subjects: 58
Study: 16549021

Group type: EXPERIMENTAL
Intervention: Seal oil administration (n-3 polyunsaturated fatty acid rich seal oil)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Soy oil administration (n-6 fatty acid rich)
Number of subjects: 29
Study: 14505773

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQOL) measured by the MOS-HIV questionnaire, specifically physical health summary (PHS) and mental health summary (MHS) scores.
Number of subjects: 957

Group type: COMPARATOR
Intervention: Health-related quality of life (HRQOL) measured by the MOS-HIV questionnaire.
Number of subjects: 957
Study: 11151866

Group type: EXPERIMENTAL
Intervention: 200 mg of erythromycin i.v.
Number of subjects: 18

Group type: COMPARATOR
Intervention: 4 mg of i.v. ondansetron (serotonin receptor antagonist) pretreatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: 12 microg/kg of i.v. atropine pretreatment
Number of subjects: 18
Study: 9127848

Group type: EXPERIMENTAL
Intervention: Operated subjects (ACL reconstruction)
Number of subjects: 15
Study: 8466682

Group type: EXPERIMENTAL
Intervention: Zidovudine 500 mg per day (group A)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Zidovudine 1000 mg per day (group B)
Number of subjects: 84
Study: 3541414

Group type: EXPERIMENTAL
Intervention: 80 mg isosorbide dinitrate (ISDN, once-daily) plus 120 mg verapamil (t.i.d.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 80 mg isosorbide dinitrate (ISDN, once-daily) plus 80 mg propranolol (b.i.d.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of all three drugs (ISDN, verapamil, propranolol)
Number of subjects: 30
Study: 30200103

Group type: EXPERIMENTAL
Intervention: Sternocleidomastoid soft tissue release (SSTR)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Suboccipital release (SR)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Comparison between SSTR and SR
Number of subjects: 17
Study: 27348720

Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IPC) - 4×5‐min occlusion at 220 mmHg/reperfusion at 0 mmHg
Number of subjects: 21

Group type: COMPARATOR
Intervention: SHAM - equal to IPC protocol but occlusion at 20 mmHg
Number of subjects: 21
Study: 24474434

Group type: EXPERIMENTAL
Intervention: Posted commitment letter intervention (displayed in examination rooms for 12 weeks)
Number of subjects: 954

Group type: COMPARATOR
Intervention: Standard practice control
Number of subjects: 954
Study: 22992762

Group type: EXPERIMENTAL
Intervention: Initiation of bisphosphonate treatment at two weeks after the operation (Group I, n = 24)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Initiation of bisphosphonate treatment at three months (Group II, n = 26)
Number of subjects: 50
Study: 20367586

Group type: EXPERIMENTAL
Intervention: Computer-based presentation (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Paper-based information statement (n = 30)
Number of subjects: 60
Study: 18272508

Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) pacing
Number of subjects: 50

Group type: COMPARATOR
Intervention: DDD(R) pacing
Number of subjects: 50
Study: 16267150

Group type: EXPERIMENTAL
Intervention: Intention to breast-feed (72% of women had this intention)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Attitude, social influence, and self-efficacy determinants
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Intention to breast-feed
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: ASE model components
Number of subjects: 373
Study: 11873025

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.17%, 14 ml, administered epidurally during the diurnal period (morning and afternoon)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Ropivacaine 0.17%, 14 ml, administered epidurally during the nocturnal period (night and evening)
Number of subjects: 194
Study: 10350384

Group type: EXPERIMENTAL
Intervention: Dirithromycin (500 mg od for 5 days)
Number of subjects: 1057

Group type: COMPARATOR
Intervention: Erythromycin (250 mg qid for 7 days)
Number of subjects: 1057
Study: 7858733

Group type: EXPERIMENTAL
Intervention: Daily subcutaneous growth hormone (GH) for 5 months
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (9 men with similar sperm counts)
Number of subjects: 12
Study: 1776803

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study: 6132524

Group type: EXPERIMENTAL
Intervention: Acebutol (400 to 800 mg daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Metoprolol (200 to 400 mg daily)
Number of subjects: 28
Study: 30998402

Group type: EXPERIMENTAL
Intervention: Suture-Spanning Augmentation of Single-Row Repair (SSA-SR)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Single-Row Repair (SR)
Number of subjects: 71
Study: 28267790

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (1-10 cigarettes per day)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (>10 cigarettes per day)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 636

Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 636
Study: 26316553

Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control (information and reassurance only)
Number of subjects: 109
Study: 24387157

Group type: EXPERIMENTAL
Intervention: High aortic pulse wave velocity (aPWV) quartile
Number of subjects: 153
Study: 22800876

Group type: EXPERIMENTAL
Intervention: Financial reinforcement interventions
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Financial reinforcement interventions (randomized studies)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Financial reinforcement interventions (longer duration, $50 or more per week, at least weekly reinforcement)
Number of subjects: 21
Study: 19132569

Group type: EXPERIMENTAL
Intervention: EHR-specific communication skills training (n=9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (n=8)
Number of subjects: 17
Study: 17578312

Group type: EXPERIMENTAL
Intervention: Liqi Kuanxiong Huoxue method (LKH) in addition to conventional treatment
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional treatment (nitrate, diltiazem hydrochloride, etc.)
Number of subjects: 51
Study: 15224278

Group type: COMPARATOR
Intervention: Placebo (group I)
Number of subjects: 573

Group type: COMPARATOR
Intervention: 5 mg/kg infliximab (group II)
Number of subjects: 573

Group type: COMPARATOR
Intervention: 5 mg/kg infliximab at weeks 2 and 6, followed by 10 mg/kg thereafter (group III)
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Immunomodulators
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Retreatment
Number of subjects: 573